Evolving Urticaria Treatment Highlights Unmet Patient Needs
Two-thirds of U.S. physicians report high unmet need in chronic spontaneous urticaria (CSU) despite two recent FDA approvals, according...
New TDP-43 PET Tracer: A Breakthrough for Precision Medicine
Preclinical data published in Nature Communications characterize AC Immune’s fluorine-18–labeled TDP-43 PET tracer, ACI-19626, showing high affinity for pathological...
Sobi’s Commitment to Rare Disease Care at ACR Convergence
In post-hoc analyses of the Phase 3 DISSOLVE trials in uncontrolled gout, nanoencapsulated sirolimus plus pegadricase (NASP) drove rapid...
Promising Phase 1 Data for KYV-101 in Rheumatoid Arthritis
In the Phase 1 portion of an investigator-initiated Phase 1/2 study in treatment-refractory rheumatoid arthritis, six patients received a...
New Hope for Nocturnal GERD: Successful Voquezna Trial
At week 4 in the Phase 3 pHalcon-NERD-301 study, patients on vonoprazan achieved mean percentages of heartburn-free nights of...
ITM-11 Shows Superior GEP-NET Response in Phase 3 Trial
Progression-free survival reached 23.9 months with 177Lu-edotreotide versus 14.1 months on everolimus in the Phase 3 COMPETE trial (HR...
Rani Therapeutics’ Surging $60.3M Private Placement Closes
Rani Therapeutics closed a $60.3 million gross private placement structured as common stock and pre-funded warrants priced at approximately...
Acrivon Highlights AP3 Platform, ACR-2316 Preclinical Data
Acrivon reported early clinical activity for its dual WEE1/PKMYT1 inhibitor ACR-2316, including a confirmed partial response during Phase 1...
Telix Doses First Patient in SOLACE Trial for Bone Pain
No efficacy data yet. Telix has initiated dosing in SOLACE, an open-label Phase 1 trial (NCT07197645) enrolling up to...
Elironrasib Safety, Efficacy Data in KRAS G12C Lung Cancer
Elironrasib delivered a confirmed objective response rate of 42% (95% CI: 22–63) and a disease control rate of 79%...